Page 35 - Managed Care News Today

Morgan Stanley downgraded shares of Centene (NYSE:CNC – Free Report) from an overweight rating to an equal weight rating in a report released on Wednesday, Marketbeat reports. The brokerage currently has $73.00 target price on the stock, down from their prior target price of $94.00. Several other research firms have also recently issued reports on […]

Morgan Stanley downgraded shares of Centene (NYSE:CNC – Free Report) from an overweight rating to an equal weight rating in a report published on Wednesday morning, Marketbeat.com reports. They currently have $73.00 price objective on the stock, down from their previous price objective of $94.00. A number of other equities research analysts also recently weighed […]

Grantham Mayo Van Otterloo & Co. LLC decreased its position in shares of Centene Co. (NYSE:CNC – Free Report) by 1.4% during the first quarter, Holdings Channel reports. The fund owned 589,602 shares of the company’s stock after selling 8,600 shares during the period. Grantham Mayo Van Otterloo & Co. LLC’s holdings in Centene were […]

Barbara Stover Gingerich, age 80, passed away on August 25, 2023, at her home with her son, Wade at her side and her grand dog, Pearl, keeping watch. She was the widow of Robert Gingerich to whom she was married 54 years. Born in Greencastle, PA on August 21 1943 to Ellis and Jane Lingg […]

Wellington Management Group LLP grew its position in Centene Co. (NYSE:CNC – Free Report) by 2.3% in the 1st quarter, according to its most recent filing with the SEC. The firm owned 20,841,828 shares of the company’s stock after buying an additional 473,747 shares during the period. Wellington Management Group LLP owned 3.80% of Centene […]

Kiana Mehring, MBA, director of strategic partnerships, managed care at Florida Cancer Specialists & Research Institute (FCS), discusses her role working in managed care and some of the new strategic partnership initiatives at FCS.

StockNews.com downgraded shares of Centene (NYSE:CNC – Free Report) from a strong-buy rating to a buy rating in a research report released on Friday. Other equities research analysts also recently issued research reports about the company. JPMorgan Chase & Co. cut their price target on Centene from $81.00 to $77.00 in a report on Friday, […]

The Biden administration has announced the first 10 drugs chosen for Medicare price negotiation, representing a major step in Democratic efforts to address health care affordability in the U.S. However, the entire program is being contested in the courts by major pharmaceutical companies and industry groups, which could potentially delay or even halt implementation, with…

The Biden administration plans to name the first 10 Medicare drugs subject to price negotiation, while pharmaceutical companies try to block the effort in court.

The British drugmaker filed a lawsuit on Friday in the U.S. District Court for the District of Delaware claiming the Inflation Reduction Act conflicts with the goals of the Orphan Drug Act.